Related references
Note: Only part of the references are listed.Focal disruption of DNA methylation dynamics at enhancers in IDH-mutant AML cells
Elisabeth R. Wilson et al.
LEUKEMIA (2022)
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study
Eytan M. Stein et al.
BLOOD (2021)
Clonal architecture predicts clinical outcomes and drug sensitivity in acute myeloid leukemia
Brooks A. Benard et al.
NATURE COMMUNICATIONS (2021)
Prognostic significance of concurrent gene mutations i n intensively treated patients with IDH-mutated AML: an ALFA study
Matthieu Duchmann et al.
BLOOD (2021)
Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia
Feng Wang et al.
NATURE COMMUNICATIONS (2021)
Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response
Wendy Beguelin et al.
CANCER CELL (2020)
Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A US Food and Drug Administration Systematic Analysis
Kelly J. Norsworthy et al.
CLINICAL CANCER RESEARCH (2020)
DNA methylation disruption reshapes the hematopoietic differentiation landscape
Franco Izzo et al.
NATURE GENETICS (2020)
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML
Sung Choe et al.
BLOOD ADVANCES (2020)
Cancers from Novel Pole-Mutant Mouse Models Provide Insights into Polymerase-Mediated Hypermutagenesis and Immune Checkpoint Blockade
Melissa A. Galati et al.
CANCER RESEARCH (2020)
Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics
Kiyomi Morita et al.
NATURE COMMUNICATIONS (2020)
Prdm16 is a critical regulator of adult long-term hematopoietic stem cell quiescence
Kristbjorn O. Gudmundsson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Single-cell mutation analysis of clonal evolution in myeloid malignancies
Linde A. Miles et al.
NATURE (2020)
Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity
Peter van Galen et al.
CELL (2019)
Comprehensive Integration of Single-Cell Data
Tim Stuart et al.
CELL (2019)
Non-catalytic Roles of Tet2 Are Essential to Regulate Hematopoietic Stem and Progenitor Cell Homeostasis
Kyoko Ito et al.
CELL REPORTS (2019)
Histone demethylase LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis
Katerina Hatzi et al.
NATURE IMMUNOLOGY (2019)
Blood disease-causing and -suppressing transcriptional enhancers: general principles and GATA2 mechanisms
Emery H. Bresnick et al.
BLOOD ADVANCES (2019)
Slingshot: cell lineage and pseudotime inference for single-cell transcriptomics
Kelly Street et al.
BMC GENOMICS (2018)
Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies
Robert L. Bowman et al.
CELL STEM CELL (2018)
DH1R132, DH2R140 and 1DH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies
Manja Meggendorfer et al.
LEUKEMIA (2018)
Integrating single-cell transcriptomic data across different conditions, technologies, and species
Andrew Butler et al.
NATURE BIOTECHNOLOGY (2018)
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib
Lynn Quek et al.
NATURE MEDICINE (2018)
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
TGF-β1 Negatively Regulates the Number and Function of Hematopoietic Stem Cells
Xiaofang Wang et al.
STEM CELL REPORTS (2018)
Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2 Analysis of a Phase 1/2 Study
Amir T. Fathi et al.
JAMA ONCOLOGY (2018)
Mutant NPM1 Maintains the Leukemic State through HOX Expression
Lorenzo Brunetti et al.
CANCER CELL (2018)
Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma
Samuel K. McBrayer et al.
CELL (2018)
Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
Andrew M. Intlekofer et al.
NATURE (2018)
Isocitrate dehydrogenase mutations in myeloid malignancies
B. C. Medeiros et al.
LEUKEMIA (2017)
An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues
M. Ryan Corces et al.
NATURE METHODS (2017)
SCENIC: single-cell regulatory network inference and clustering
Sara Aibar et al.
NATURE METHODS (2017)
Overexpression of SOX4 correlates with poor prognosis of acute myeloid leukemia and is leukemogenic in zebrafish
J-W Lu et al.
BLOOD CANCER JOURNAL (2017)
Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia
Alan H. Shih et al.
CANCER DISCOVERY (2017)
Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers
Jacob L. Glass et al.
CANCER DISCOVERY (2017)
TET2 in Normal and Malignant Hematopoiesis
Robert L. Bowman et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2017)
The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia
Adam S. Sperling et al.
NATURE REVIEWS CANCER (2017)
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response
Michael D. Amatangelo et al.
BLOOD (2017)
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein et al.
BLOOD (2017)
IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression
C. D. DiNardo et al.
LEUKEMIA (2016)
Integrated genome-scale analysis of the transcriptional regulatory landscape in a blood stem/progenitor cell model
Nicola K. Wilson et al.
BLOOD (2016)
Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2
Satoshi Inoue et al.
CANCER CELL (2016)
MED12 Regulates HSC-Specific Enhancers Independently of Mediator Kinase Activity to Control Hematopoiesis
Beatriz Aranda-Orgilles et al.
CELL STEM CELL (2016)
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development
Francois Lemonnier et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Acute myeloid leukaemia
Asim Khwaja et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
Steven M. Chan et al.
NATURE MEDICINE (2015)
Metabolic consequences of oncogenic IDH mutations
Seth J. Parker et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Combined Loss of Tet1 and Tet2 Promotes B Cell, but Not Myeloid Malignancies, in Mice
Zhigang Zhao et al.
CELL REPORTS (2015)
Cis-regulatory mechanisms governing stem and progenitor cell transitions
Kirby D. Johnson et al.
SCIENCE ADVANCES (2015)
Regulation of MEIS1 by distal enhancer elements in acute leukemia
Q-f Wang et al.
LEUKEMIA (2014)
Delineating MEIS1 cis-regulatory elements active in hematopoietic cells
P. Xiang et al.
LEUKEMIA (2014)
Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
Giulio Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
Siddhartha Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C > T have a prognostic value in acute myeloid leukemia
Kerstin Willander et al.
BIOMARKER RESEARCH (2014)
Sox4 Is a Key Oncogenic Target in C/EBPα Mutant Acute Myeloid Leukemia
Hong Zhang et al.
CANCER CELL (2013)
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
Julie-Aurore Losman et al.
GENES & DEVELOPMENT (2013)
The Potential for Isocitrate Dehydrogenase Mutations to Produce 2-Hydroxyglutarate Depends on Allele Specificity and Subcellular Compartmentalization
Patrick S. Ward et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities
Rob A. Cairns et al.
CANCER DISCOVERY (2013)
Targeting oncogenic Ras signaling in hematologic malignancies
Ashley F. Ward et al.
BLOOD (2012)
Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters
Francois Lemonnier et al.
BLOOD (2012)
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma
Rob A. Cairns et al.
BLOOD (2012)
Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement
Maryam Arefi et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2012)
Cis-element mutated in GATA2-dependent immunodeficiency governs hematopoiesis and vascular integrity
Kirby D. Johnson et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis
Lambert Busque et al.
NATURE GENETICS (2012)
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Jay P. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The role of mutations in epigenetic regulators in myeloid malignancies
Alan H. Shih et al.
NATURE REVIEWS CANCER (2012)
Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia
Nicolas Boissel et al.
BLOOD (2011)
The prognostic significance of IDH2 mutations in AML depends on the location of the mutation
Claire L. Green et al.
BLOOD (2011)
Prdm16 is a physiologic regulator of hematopoietic stem cells
Francesca Aguilo et al.
BLOOD (2011)
TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis
Cyril Quivoron et al.
CANCER CELL (2011)
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Wei Xu et al.
CANCER CELL (2011)
Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid Transformation
Kelly Moran-Crusio et al.
CANCER CELL (2011)
Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice
Myunggon Ko et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia
Felicitas Thol et al.
BLOOD (2010)
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
Patrick S. Ward et al.
CANCER CELL (2010)
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Maria E. Figueroa et al.
CANCER CELL (2010)
Distinct Hematopoietic Stem Cell Subtypes Are Differentially Regulated by TGF-β1
Grant A. Challen et al.
CELL STEM CELL (2010)
Combinatorial Transcriptional Control In Blood Stem/Progenitor Cells: Genome-wide Analysis of Ten Major Transcriptional Regulators
Nicola K. Wilson et al.
CELL STEM CELL (2010)
IDH1 and IDH2 Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
Guido Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication
Peter Paschka et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prdm16 promotes stem cell maintenance in multiple tissues, partly by regulating oxidative stress
Sergei Chuikov et al.
NATURE CELL BIOLOGY (2010)
Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms
Anna M. Jankowska et al.
BLOOD (2009)
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
A. Tefferi et al.
LEUKEMIA (2009)
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Lenny Dang et al.
NATURE (2009)
Acquired mutations in TET2 are common in myelodysplastic syndromes
Saskia M. C. Langemeijer et al.
NATURE GENETICS (2009)
Mutation in TET2 in Myeloid Cancers
Francois Delhommeau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
Elaine R. Mardis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Conditional c-myb knockout in adult hematopoietic stem cells leads to loss of self-renewal due to impaired proliferation and accelerated differentiation
Yen K. Lieu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Role of platelet-derived growth factors in physiology and medicine
Johanna Andrae et al.
GENES & DEVELOPMENT (2008)
Transgenic mice with hematopoietic and lymphoid specific expression of Cre
J de Boer et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta
JF Apperley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
